US molecular imaging extends these capabilities by enabling early diagnosis and therapeutic monitoring at the molecular level through the use of targeted nanobubbles that bind specifically to tumor biomarkers such as VEGFR2 and PD-L1. This evidence concerns the gene KDR and neoplasm.